RxSight
RXST
192 hedge funds and large institutions have $923M invested in RxSight in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 94 increasing their positions, 48 reducing their positions, and 42 closing their positions.
3,444% more call options, than puts
Call options by funds: $8.04M | Put options by funds: $227K
96% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 48
2.67% more ownership
Funds ownership: 87.65% → 90.32% (+2.7%)
9% less funds holding
Funds holding: 212 → 192 (-20)
24% less capital invested
Capital invested by funds: $1.21B → $923M (-$291M)
45% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 42
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$19.2M |
| 2 |
DM
Deerfield Management
New York
|
+$11.7M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$9.82M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$6.42M |
| 5 |
Credit Agricole
Montrouge Cedex,
France
|
+$5.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$22.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$11M |
| 3 |
OCM
Osterweis Capital Management
San Francisco,
California
|
-$9.9M |
| 4 |
ACM
Altium Capital Management
New York
|
-$9.8M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$7.71M |
RXST Hedge Fund Activity: Q1 2025 in Review
192 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in RxSight (RXST) for Q1 2025, worth a combined $923M — down 24% from $1.21B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of RXST and 23 opened new positions — a net loss of 19 holders — while 48 trimmed existing stakes and 94 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $19.2M. The largest seller was Citadel Advisors, cutting an estimated $22.7M.
- 192 institutional investors held RxSight (RXST) as of Q1 2025, down from 212 in Q4 2024.
- Funds reported $923M of RxSight stock for Q1 2025, down 24% quarter-over-quarter.
- 23 funds opened new RxSight positions in Q1 2025 and 42 closed out, a net change of -19 holders.
- The largest RxSight buyer in Q1 2025 was T. Rowe Price Investment Management, an estimated $19.2M added.
- The largest RxSight seller in Q1 2025 was Citadel Advisors, an estimated $22.7M sold.
Based on aggregated 13F filings for Q1 2025.